| Literature DB >> 29479336 |
Araz Al-Saffar1, Bassam Al-Fatly2.
Abstract
Guillain-Barré syndrome (GBS) is an acute peripheral neuropathy that develops as a result of post-infectious immune-mediated nerve injury. It can be classified into classic and variant GBS. Acute motor axonal neuropathy (AMAN) is a subtype of GBS with the key clinical features of pure motor weakness, areflexia, absence of sensory symptoms, and lack of neurophysiologic evidence of demyelination. We reported a case of acute motor axonal neuropathy in association with hepatitis E infection. A young woman was referred to us after a period of nausea, fever, and diarrhea. She had unexplained muscle weakness at admission and has been diagnosed with acute hepatitis E infection. A rigorous clinical neurological assessment revealed bilateral symmetrical weakness, which affects the lower limbs more than the upper limbs, with no evidence of sensory involvement. Neurophysiological measurements indicated acute axonal injury without clues to demyelination. A diagnosis of acute motor axonal neuropathy subtype has been made, to which she only received supportive therapy. The symptoms resolved spontaneously and full recovery of motor function was attained after 35 days of weakness onset with complete normalization of neurophysiologic parameters.Entities:
Keywords: Guillain–Barré syndrome; acute motor axonal neuropathy; hepatitis E; muscle weakness; nerve conduction study
Year: 2018 PMID: 29479336 PMCID: PMC5811470 DOI: 10.3389/fneur.2018.00062
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Comparison of motor nerve conduction study (NCS) results at onset and resolution of motor weakness.
| Parameters | R. sural | L. sural | R. peroneal | L. peroneal | R. tibial | L. tibial | R. median | L. median | R. ulnar | L. ulnar |
|---|---|---|---|---|---|---|---|---|---|---|
| dCMAP amp. (mV) | 0.5 | 0.7 | 2.1 | 1.9 | 3.8 | 4.0 | 3.2 | 3.4 | ||
| Normal values (mV) | >2.0 | >4.0 | >4.4 | >6.0 | ||||||
| DML (ms) | 4.2 | 4.1 | 3.0 | 3.1 | 2.4 | 2.5 | 2.46 | 2.75 | ||
| Normal values (ms) | <6.5 | <5.8 | <4.2 | <3.1 | ||||||
| MCV (m/s) | 51.7 | 50.7 | 49.1 | 50.1 | 58.8 | 57.0 | 54.7 | 54.0 | ||
| Normal values (m/s) | >40 | >40 | >50 | >50 | ||||||
| SNAP amp. (μV) | 14 | 15 | 23 | 22 | 21 | 24 | ||||
| Normal values (μV) | >10 | >20 | >18 | |||||||
| SCV (m/s) | 55.2 | 54.3 | 63.3 | 61.2 | 60.3 | 60.9 | ||||
| Normal values (m/s) | >36 | >45 | >44 | |||||||
| dCMAP amp. (mV) | 4.3 | 4.1 | 4.3 | 4.7 | 5.0 | 5.3 | 4.9 | 5.1 | ||
| DML (ms) | 3.7 | 3.9 | 2.6 | 3.0 | 2.3 | 2.4 | 2.6 | 2.9 | ||
| CV (m/s) | 57.7 | 58.8 | 50.2 | 51.0 | 58.9 | 56.9 | 52.2 | 52.1 | ||
| SNAP amp. (μV) | 16 | 13 | 24 | 21 | 23 | - | ||||
| SCV (m/s) | 53.5 | 52.1 | 62.5 | 60.8 | 59.4 | - | ||||
R, right; L, left; dCMAP, distal compound muscle action potential amplitude; MCV, motor conduction velocity; SCV, sensory conduction velocity; SNAP, sensory nerve action potential.